 | |
| Formerly | Chiros |
|---|---|
| formerly on the London Stock Exchange | |
| Founded | 1991 [1] |
| Founder |
|
| Defunct | 1999 |
| Fate | Acquired by Celltech |
Key people | John Padfield CEO, 1996 [2] |
Chiroscience Group Plc was a British-based biotech company, founded by Christopher Evans. The company was taken over by Celltech in 1999, [3] which was acquired in 2004 by UCB.
Chiroscience was born from the demise of the company Enzymatix, which was ultimately acquired by Genzyme, [4] when Andrew Richards joined the company and convinced Evans and Peter Keen to launch Chiros, which name was quickly revised to Chrioscience. [3] Seed funding for the company of GB£3 million was provided by Schroder Ventures, Apax and 3i. [3] Chiroscience became one of the first biotechnology Initial Public Offerings in the United Kingdom in 1994. [3]
In 1996, the company merged with the American biotech company Darwin Molecular Corporation, based in Cambridge, Massachusetts, retaining Chiroscience as its name. [2]
By the time of its merger with Celltech in 1999, [5] both Chris Evans and Peter Keen had left the company, leaving Andrew Richards as the sole remaining founder and member of the original management board. [3]
On Mr. Buffet's terms, Chiroscience is nothing more than a bag of dreams.Contains a graphic showing company stock performance across 1994 to 1996.
 | This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it. |
British Aerospace plc (BAe) was a British aircraft, munitions and defence-systems manufacturer. Its head office was at Warwick House in the Farnborough Aerospace Centre in Farnborough, Hampshire. Formed in 1977, in 1999 it purchased Marconi Electronic Systems, the defence electronics and naval shipbuilding subsidiary of the General Electric Company plc, to form BAE Systems.
BAE Systems plc (BAE) is a British multinational arms, security, and aerospace company based in London, England. The company is the largest defence contractor in Europe and among the world's largest defence companies; it was ranked as the third-largest based on applicable 2017 revenues. Its largest operations are in the United Kingdom and United States, where its BAE Systems Inc. subsidiary is one of the six largest suppliers to the US Department of Defense. Other major markets include Australia, India, and Saudi Arabia, which account for about 20% of BAE's overall sales. It is the biggest manufacturer in Britain. The company was formed on 30 November 1999 by the £7.7 billion purchase and merger of Marconi Electronic Systems (MES)—the defence electronics and naval shipbuilding subsidiary of the General Electric Company plc (GEC)—by British Aerospace, an aircraft, munitions and naval systems manufacturer.
AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. It has been involved in developing the Oxford-AstraZeneca COVID-19 vaccine.
The Financial Times Stock Exchange 100 Index, also called the FTSE 100 Index, FTSE 100, FTSE, or, informally, the "Footsie", is a share index of the 100 companies listed on the London Stock Exchange with the highest market capitalisation. The index is maintained by the FTSE Group, a subsidiary of the London Stock Exchange Group.
Sanofi S.A. is a French multinational pharmaceutical corporation headquartered in Paris, France, as of 2013 the world's fifth-largest by prescription sales. Originally, the corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers. It changed its name back to Sanofi in May 2011. The company is a component of the Euro Stoxx 50 stock market index.
Ladbrokes Coral is a British betting and gambling company. It is based in London. It previously owned the Hilton hotel brand outside the United States, and was known as Hilton Group plc from 1999 to 2006. In November 2016, Ladbrokes acquired Gala Coral Group, and changed its name to Ladbrokes Coral.
UCB is a multinational biopharmaceutical company headquartered in Brussels, Belgium. UCB is an international company with a revenue of €4.178 billion in 2016 which focuses primarily on research and development, specifically involving medications centered on epilepsy, Parkinson's, and Crohn's diseases. The company's efforts are focused on treatments for severe diseases treated by specialists, particularly in the fields of central nervous system (CNS) disorders, inflammatory disorders, and oncology.
Sanofi Genzyme is an American biotechnology company based in Cambridge, Massachusetts. Since its acquisition in 2011, Genzyme has been a fully owned subsidiary of Sanofi. In 2010, Genzyme was the world’s third-largest biotechnology company, employing more than 11,000 people around the world. As a subsidiary of Sanofi, Genzyme has a presence in approximately 65 countries, including 17 manufacturing facilities and 9 genetic-testing laboratories. Its products are also sold in 90 countries. In 2007, Genzyme generated $3.8 billion in revenue with more than 25 products on the market. In 2006 and 2007, Genzyme was named one of Fortune magazine’s “100 Best Companies to Work for”. The company donated $83 million worth of products worldwide; in 2006, it made $11 million in cash donations. In 2005, Genzyme was awarded the National Medal of Technology, the highest level of honor awarded by the president of the United States to America’s leading innovators.
Celltech Group plc was a leading British-based biotechnology business based in Slough. It was listed on the London Stock Exchange and was a constituent of the FTSE 100 Index.
Sheridan Gray Snyder OBE is an entrepreneur, venture capitalist, and philanthropist in the biotechnology industry. He is the founder and CEO of Biocatalyst, but also a "serial entrepreneur", a founder of Genzyme and many other companies. Snyder, who was the University of Virginia's best tennis player when he was studying for his BA in French and Romance Languages there in the 1960s, made "major contributions to the popularisation of tennis in the USA." He co-founded the National Junior Tennis League that reaches 250,000 inner-city young people and constructed a new tennis center at the University of Virginia.
Sir Christopher Thomas Evans is a Welsh biotechnology entrepreneur.
Janssen Vaccines, formerly Crucell, is a biotechnology company specializing in vaccines and biopharmaceutical technologies. It was formed when Johnson & Johnson acquired the Dutch biotech company Crucell based in Leiden and placed it in their pharmaceutical division.
Buena Vista is a brand name that was historically often used for divisions and subsidiaries of The Walt Disney Company, whose primary studios, the Walt Disney Studios, are located on Buena Vista Street in Burbank, California. The studio lot is also home to the company's corporate headquarters, the Team Disney Burbank building.
Cambridge Antibody Technology was a biotechnology company headquartered in Cambridge, England, United Kingdom. Its core focus was on antibody therapeutics, primarily using Phage Display and Ribosome Display technology.
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Sorrento Valley, San Diego, California.
Romosozumab, sold under the brand name Evenity, is a medication used to treat osteoporosis. It has been found to decrease the risk of fractures of the spine.
AAH is a pharmaceutical wholesaler in the United Kingdom. Originally formed in 1892 as a company selling solid fuels in South Wales, it was floated on the stock exchange in 1923. It diversified into pharmaceuticals in the 1970s, and since 1995 it has been a subsidiary of the German company Celesio AG.
STV Group plc is a media company based in Glasgow, Scotland. Beginning as a television broadcaster in 1957, the company expanded into newspapers, advertising and radio; after completing a restructuring in 2010, STV Group is active in broadcast television, video-on-demand and television production. The company is a constituent of the FTSE SmallCap Index.
Henri A. Termeer was a Dutch biotechnology executive and entrepreneur who is considered a pioneer in corporate strategy in the biotechnology industry for his tenure as CEO at Genzyme. Termeer created a business model adopted by many others in the biotech industry by garnering steep prices— mainly from insurers and government payers— for therapies for rare genetic disorders known as orphan diseases that mainly affect children. Genzyme uses biological processes to manufacture drugs that are not easily copied by generic-drug makers. The drugs are also protected by orphan drug acts in various countries which provides extensive protection from competition and ensures coverage by publicly funded insurers. As CEO of Genzyme from 1981 to 2011, he developed corporate strategies for growth including optimizing institutional embeddedness nurturing vast networks of influential groups and clusters: doctors, private equity, patient-groups, insurance, healthcare umbrella organizations, state and local government, alumni. Termeer is "connected to 311 board members in 17 different organizations across 20 different industries" He has the legacy of being the "longest-serving CEO in the biotechnology industry.
Ionis Pharmaceuticals is a biotechnology company based in Carlsbad, California that specializes in discovering and developing RNA-targeted therapeutics. The company has 3 commercially approved medicines: Spinraza (Nusinersen), Tegsedi (Inotersen), and Waylivra (Volanesorsen) and has 4 drugs in pivotal studies: tominersen for Huntington’s disease, tofersen for SOD1-ALS, AKCEA-APO(a)-LRx for cardiovascular disease, and AKCEA-TTR-LRx for all forms of TTR amyloidosis.
